Cargando…

Compounds identified by virtual docking to a tetrameric EGFR extracellular domain can modulate Grb2 internalization

BACKGROUND: Overexpression or mutation of the epidermal growth factor receptor (EGFR) potently enhances the growth of many solid tumors. Tumor cells frequently display resistance to mechanistically-distinct EGFR-directed therapeutic agents, making it valuable to develop therapeutics that work by add...

Descripción completa

Detalles Bibliográficos
Autores principales: Ramirez, Ursula D., Nikonova, Anna S., Liu, Hanqing, Pecherskaya, Anna, Lawrence, Sarah H., Serebriiskii, Ilya G., Zhou, Yan, Robinson, Matthew K., Einarson, Margret B., Golemis, Erica A., Jaffe, Eileen K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4451962/
https://www.ncbi.nlm.nih.gov/pubmed/26016476
http://dx.doi.org/10.1186/s12885-015-1415-6
_version_ 1782374226587549696
author Ramirez, Ursula D.
Nikonova, Anna S.
Liu, Hanqing
Pecherskaya, Anna
Lawrence, Sarah H.
Serebriiskii, Ilya G.
Zhou, Yan
Robinson, Matthew K.
Einarson, Margret B.
Golemis, Erica A.
Jaffe, Eileen K.
author_facet Ramirez, Ursula D.
Nikonova, Anna S.
Liu, Hanqing
Pecherskaya, Anna
Lawrence, Sarah H.
Serebriiskii, Ilya G.
Zhou, Yan
Robinson, Matthew K.
Einarson, Margret B.
Golemis, Erica A.
Jaffe, Eileen K.
author_sort Ramirez, Ursula D.
collection PubMed
description BACKGROUND: Overexpression or mutation of the epidermal growth factor receptor (EGFR) potently enhances the growth of many solid tumors. Tumor cells frequently display resistance to mechanistically-distinct EGFR-directed therapeutic agents, making it valuable to develop therapeutics that work by additional mechanisms. Current EGFR-targeting therapeutics include antibodies targeting the extracellular domains, and small molecules inhibiting the intracellular kinase domain. Recent studies have identified a novel prone extracellular tetrameric EGFR configuration, which we identify as a potential target for drug discovery. METHODS: Our focus is on the prone EGFR tetramer, which contains a novel protein-protein interface involving extracellular domain III. This EGFR tetramer is computationally targeted for stabilization by small molecule ligand binding. This study performed virtual screening of a Life Chemicals, Inc. small molecule library of 345,232 drug-like compounds against a molecular dynamics simulation of protein-protein interfaces distinct to the novel tetramer. One hundred nine chemically diverse candidate molecules were selected and evaluated using a cell-based high-content imaging screen that directly assessed induced internalization of the EGFR effector protein Grb2. Positive hits were further evaluated for influence on phosphorylation of EGFR and its effector ERK1/2. RESULTS: Fourteen hit compounds affected internalization of Grb2, an adaptor responsive to EGFR activation. Most hits had limited effect on cell viability, and minimally influenced EGFR and ERK1/2 phosphorylation. Docked hit compound poses generally include Arg270 or neighboring residues, which are also involved in binding the effective therapeutic cetuximab, guiding further chemical optimization. CONCLUSIONS: These data suggest that the EGFR tetrameric configuration offers a novel cancer drug target. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-015-1415-6) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4451962
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-44519622015-06-03 Compounds identified by virtual docking to a tetrameric EGFR extracellular domain can modulate Grb2 internalization Ramirez, Ursula D. Nikonova, Anna S. Liu, Hanqing Pecherskaya, Anna Lawrence, Sarah H. Serebriiskii, Ilya G. Zhou, Yan Robinson, Matthew K. Einarson, Margret B. Golemis, Erica A. Jaffe, Eileen K. BMC Cancer Research Article BACKGROUND: Overexpression or mutation of the epidermal growth factor receptor (EGFR) potently enhances the growth of many solid tumors. Tumor cells frequently display resistance to mechanistically-distinct EGFR-directed therapeutic agents, making it valuable to develop therapeutics that work by additional mechanisms. Current EGFR-targeting therapeutics include antibodies targeting the extracellular domains, and small molecules inhibiting the intracellular kinase domain. Recent studies have identified a novel prone extracellular tetrameric EGFR configuration, which we identify as a potential target for drug discovery. METHODS: Our focus is on the prone EGFR tetramer, which contains a novel protein-protein interface involving extracellular domain III. This EGFR tetramer is computationally targeted for stabilization by small molecule ligand binding. This study performed virtual screening of a Life Chemicals, Inc. small molecule library of 345,232 drug-like compounds against a molecular dynamics simulation of protein-protein interfaces distinct to the novel tetramer. One hundred nine chemically diverse candidate molecules were selected and evaluated using a cell-based high-content imaging screen that directly assessed induced internalization of the EGFR effector protein Grb2. Positive hits were further evaluated for influence on phosphorylation of EGFR and its effector ERK1/2. RESULTS: Fourteen hit compounds affected internalization of Grb2, an adaptor responsive to EGFR activation. Most hits had limited effect on cell viability, and minimally influenced EGFR and ERK1/2 phosphorylation. Docked hit compound poses generally include Arg270 or neighboring residues, which are also involved in binding the effective therapeutic cetuximab, guiding further chemical optimization. CONCLUSIONS: These data suggest that the EGFR tetrameric configuration offers a novel cancer drug target. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-015-1415-6) contains supplementary material, which is available to authorized users. BioMed Central 2015-05-28 /pmc/articles/PMC4451962/ /pubmed/26016476 http://dx.doi.org/10.1186/s12885-015-1415-6 Text en © Ramirez et al. 2015
spellingShingle Research Article
Ramirez, Ursula D.
Nikonova, Anna S.
Liu, Hanqing
Pecherskaya, Anna
Lawrence, Sarah H.
Serebriiskii, Ilya G.
Zhou, Yan
Robinson, Matthew K.
Einarson, Margret B.
Golemis, Erica A.
Jaffe, Eileen K.
Compounds identified by virtual docking to a tetrameric EGFR extracellular domain can modulate Grb2 internalization
title Compounds identified by virtual docking to a tetrameric EGFR extracellular domain can modulate Grb2 internalization
title_full Compounds identified by virtual docking to a tetrameric EGFR extracellular domain can modulate Grb2 internalization
title_fullStr Compounds identified by virtual docking to a tetrameric EGFR extracellular domain can modulate Grb2 internalization
title_full_unstemmed Compounds identified by virtual docking to a tetrameric EGFR extracellular domain can modulate Grb2 internalization
title_short Compounds identified by virtual docking to a tetrameric EGFR extracellular domain can modulate Grb2 internalization
title_sort compounds identified by virtual docking to a tetrameric egfr extracellular domain can modulate grb2 internalization
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4451962/
https://www.ncbi.nlm.nih.gov/pubmed/26016476
http://dx.doi.org/10.1186/s12885-015-1415-6
work_keys_str_mv AT ramirezursulad compoundsidentifiedbyvirtualdockingtoatetramericegfrextracellulardomaincanmodulategrb2internalization
AT nikonovaannas compoundsidentifiedbyvirtualdockingtoatetramericegfrextracellulardomaincanmodulategrb2internalization
AT liuhanqing compoundsidentifiedbyvirtualdockingtoatetramericegfrextracellulardomaincanmodulategrb2internalization
AT pecherskayaanna compoundsidentifiedbyvirtualdockingtoatetramericegfrextracellulardomaincanmodulategrb2internalization
AT lawrencesarahh compoundsidentifiedbyvirtualdockingtoatetramericegfrextracellulardomaincanmodulategrb2internalization
AT serebriiskiiilyag compoundsidentifiedbyvirtualdockingtoatetramericegfrextracellulardomaincanmodulategrb2internalization
AT zhouyan compoundsidentifiedbyvirtualdockingtoatetramericegfrextracellulardomaincanmodulategrb2internalization
AT robinsonmatthewk compoundsidentifiedbyvirtualdockingtoatetramericegfrextracellulardomaincanmodulategrb2internalization
AT einarsonmargretb compoundsidentifiedbyvirtualdockingtoatetramericegfrextracellulardomaincanmodulategrb2internalization
AT golemisericaa compoundsidentifiedbyvirtualdockingtoatetramericegfrextracellulardomaincanmodulategrb2internalization
AT jaffeeileenk compoundsidentifiedbyvirtualdockingtoatetramericegfrextracellulardomaincanmodulategrb2internalization